Drugs / IBI3042
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07842393 | Sep 2026 → Feb 2027 expected | — | Fortvita Biologics (USA)Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07793019 | Sep 2026 → Sep 2027 expected | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07802899 | Sep 2026 → Mar 2027 expected | obesity disorder | Hongwei Jiang | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI3042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07802899 ↗ |
| Action | Activate | “activates the glucagon-like peptide-1 (GLP-1) receptor.” NCT07802899 ↗ |
| Route | Oral | “IBI3042,oral. Corresponding dose regimen according to study cohort.” NCT07793019 ↗ |